SIOP-PODC Adapted Risk Stratification and Treatment Guidelines: Recommendations for Neuroblastoma in Low- and Middle-income Settings

Overview

Journal Pediatr Blood Cancer

Specialties Hematology
Oncology
Pediatrics

Date 2015 Mar 27

PMID 25810263

Citations 29

Authors

Nehal S Parikh

Scott C Howard

Guillermo Chantada

Trijn Israels

Mohammed Khattab

Patricia Alcasabas

Catherine G Lam

Lawrence Faulkner

Julie R Park

Wendy B London

Katherine K Matthay

Affiliations

Soon will be listed here.

Abstract

Neuroblastoma is the most common extracranial solid tumor in childhood in high-income countries (HIC), where consistent treatment approaches based on clinical and tumor biological risk stratification have steadily improved outcomes. However, in low- and middle- income countries (LMIC), suboptimal diagnosis, risk stratification, and treatment may occur due to limited resources and unavailable infrastructure. The clinical practice guidelines outlined in this manuscript are based on current published evidence and expert opinions. Standard risk stratification and treatment explicitly adapted to graduated resource settings can improve outcomes for children with neuroblastoma by reducing preventable toxic death and relapse.

Citing Articles

Exploring treatment decision-making at diagnosis for children with advanced cancer in low- and middle-income countries.

Salek M, Porter A, Maradiege E, Dolendo M, Figueredo D, Geriga F Support Care Cancer. 2024; 32(11):753.

PMID: 39472335 PMC: 11522104. DOI: 10.1007/s00520-024-08951-z.

Using context-specific evidence to inform resource-stratified cancer guidelines: A call for a new approach.

Buckle G, DeBoer R, Xu M, Mrema A, Rubagumya F, Velloza J Cancer. 2024; 131(1):e35573.

PMID: 39306723 PMC: 11694159. DOI: 10.1002/cncr.35573.

Optimising Palliative Care for Children with Metastatic Neuroblastoma and the Paediatrician's Role in a Shared Care Model - Proposal from a Regional Cancer Centre in India.

Nair M, Thankamony P, Rajeswari B, Guruprasad C, Prasanth V, Prasanth C Indian J Palliat Care. 2024; 30(2):163-167.

PMID: 38846133 PMC: 11152510. DOI: 10.25259/IJPC_254_2022.

Understanding treatment recommendations at diagnosis of advanced cancer in pediatric oncology: The need to explore decision-making challenges globally.

Force L, Hlatywayo L, Salek M, Bhakta M, Bonilla M, Kaye E Pediatr Blood Cancer. 2024; 71(4):e30854.

PMID: 38233986 PMC: 10922856. DOI: 10.1002/pbc.30854.

Dispensing Oral Temozolomide in Children: Precision and Stability of a Novel and Ready to Use Liquid Formulation in Comparison with Capsule Derived Mixtures.

Lemarchand C, Bienayme H, Rieutord A, Abbou S, Annereau M, Bastid J Pharmaceutics. 2023; 15(12).

PMID: 38140052 PMC: 10747876. DOI: 10.3390/pharmaceutics15122711.

References

Schmidt M, Lal A, Seeger R, Maris J, Shimada H, OLeary M . Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a Children's Cancer Group Study. J Clin Oncol. 2005; 23(27):6474-80. DOI: 10.1200/JCO.2005.05.183. View

Russell H, Groshen S, Ara T, DeClerck Y, Hawkins R, Jackson H . A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer. 2011; 57(2):275-82. PMC: 3117015. DOI: 10.1002/pbc.22821. View

Robison N, Campigotto F, Chi S, Manley P, Turner C, Zimmerman M . A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. Pediatr Blood Cancer. 2013; 61(4):636-42. PMC: 4285784. DOI: 10.1002/pbc.24794. View

Valteau-Couanet D, Michon J, Boneu A, Rodary C, Perel Y, Bergeron C . Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French Society of Pediatric Oncology (SFOP) protocol. J Clin Oncol. 2005; 23(3):532-40. DOI: 10.1200/JCO.2005.03.054. View

Valteau-Couanet D, Le Deley M, Bergeron C, Ducassou S, Michon J, Rubie H . Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy. Pediatr Blood Cancer. 2013; 61(6):977-81. DOI: 10.1002/pbc.24713. View

Castleberry R, Pritchard J, Ambros P, Berthold F, Brodeur G, Castel V . The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer. 1998; 33(12):2113-6. DOI: 10.1016/s0959-8049(97)00202-5. View

Rubie H, Coze C, Plantaz D, Munzer C, Defachelles A, Bergeron C . Localised and unresectable neuroblastoma in infants: excellent outcome with low-dose primary chemotherapy. Br J Cancer. 2003; 89(9):1605-9. PMC: 2394428. DOI: 10.1038/sj.bjc.6601259. View

Parise I, Haddad B, Cavalli L, Pianovski M, Maggio E, Parise G . Neuroblastoma in southern Brazil: an 11-year study. J Pediatr Hematol Oncol. 2006; 28(2):82-7. DOI: 10.1097/01.mph.0000199601.35010.52. View

Bagatell R, Beck-Popovic M, London W, Zhang Y, Pearson A, Matthay K . Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database. J Clin Oncol. 2008; 27(3):365-70. PMC: 2651034. DOI: 10.1200/JCO.2008.17.9184. View

10.

Coze C, Hartmann O, Michon J, Frappaz D, Dusol F, Rubie H . NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology. J Clin Oncol. 1997; 15(12):3433-40. DOI: 10.1200/JCO.1997.15.12.3433. View

11.

Soni S, Pai V, Gross T, Ranalli M . Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high-risk neuroblastoma: early results from a single institution. Pediatr Transplant. 2013; 18(2):217-20. DOI: 10.1111/petr.12202. View

12.

Israels T, Moreira C, Scanlan T, Molyneux L, Kampondeni S, Hesseling P . SIOP PODC: clinical guidelines for the management of children with Wilms tumour in a low income setting. Pediatr Blood Cancer. 2012; 60(1):5-11. DOI: 10.1002/pbc.24321. View

13.

Veal G, Nguyen L, Paci A, Riggi M, Amiel M, Valteau-Couanet D . Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial. Eur J Cancer. 2012; 48(16):3063-72. DOI: 10.1016/j.ejca.2012.05.020. View

14.

Baker D, Schmidt M, Cohn S, Maris J, London W, Buxton A . Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med. 2010; 363(14):1313-23. PMC: 2993160. DOI: 10.1056/NEJMoa1001527. View

15.

Bagatell R, Rumcheva P, London W, Cohn S, Look A, Brodeur G . Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol. 2005; 23(34):8819-27. DOI: 10.1200/JCO.2004.00.2931. View

16.

Strother D, London W, Schmidt M, Brodeur G, Shimada H, Thorner P . Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641. J Clin Oncol. 2012; 30(15):1842-8. PMC: 3383182. DOI: 10.1200/JCO.2011.37.9990. View

17.

Gurney J, Davis S, Severson R, Fang J, Ross J, Robison L . Trends in cancer incidence among children in the U.S. Cancer. 1996; 78(3):532-41. DOI: 10.1002/(SICI)1097-0142(19960801)78:3<532::AID-CNCR22>3.0.CO;2-Z. View

18.

Monclair T, Brodeur G, Ambros P, Brisse H, Cecchetto G, Holmes K . The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):298-303. PMC: 2650389. DOI: 10.1200/JCO.2008.16.6876. View

19.

Cohn S, Pearson A, London W, Monclair T, Ambros P, Brodeur G . The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2008; 27(2):289-97. PMC: 2650388. DOI: 10.1200/JCO.2008.16.6785. View

20.

Dubois S, Kalika Y, Lukens J, Brodeur G, Seeger R, Atkinson J . Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999; 21(3):181-9. DOI: 10.1097/00043426-199905000-00005. View